Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2022-02-02 00:00:00 ET · period of report 2022-01-31 · accession 0001209191-22-006596 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-02 | 2022-01-31 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +19.9K | 43.3K | +85% | $0 |
| D | 2022-02-02 | 2022-01-31 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $11.73 | -19.9K | 23.5K | -46% | -$232.9K |
| D | 2022-02-02 | 2022-01-31 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -19.9K | 7.76M | -0.3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-01-31 | C | A | 19,858 | $0.00 | 43,328 | D | — | — | |
| 2 | Common | Class A Common Stock | 2022-01-31 | S | D | 19,858 | $11.73 | 23,470 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $11.43 to $11.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Derivative | Class B Common Stock | 2022-01-31 | C | D | 19,858 | $0.00 | 7,758,484 | D | $0.00 · — to — | 19,858 Class A Common Stock | (F4) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |